Penetration enhancement creates the pharmacological infrastructure: Tretinoin's stratum corneum permeabilization effect increases the follicular bioavailability of minoxidil, finasteride, and progesterone simultaneously — meaning the co-formulation of tretinoin improves not just its own delivery but the effective dose of every other active in the formula reaching the perifollicular dermis. This is the pharmacological interaction that makes the four-active combination produce outcomes that are genuinely greater than the sum of parts.

Dual-isoform DHT suppression: Finasteride inhibits type II 5-alpha reductase; progesterone inhibits type I and adds receptor-level competition. Together they address DHT synthesis through both primary isoforms expressed in scalp tissue and protect follicular androgen receptors from residual DHT signaling — producing more complete androgenic protection than any single anti-androgenic active achieves alone.

Anti-androgenic foundation enables growth stimulation: With DHT-driven follicular miniaturization suppressed by the dual anti-androgenic coverage of finasteride and progesterone, minoxidil's anagen prolongation, vasodilation, and dermal papilla stimulation work on follicles that are no longer being actively pushed toward regression. The two mechanisms are genuinely synergistic: anti-androgenic therapy stops the loss; minoxidil drives the recovery.

Tretinoin's follicular cellular activity complements vascular and hormonal mechanisms: Beyond penetration enhancement, tretinoin's direct RAR-mediated follicular keratinocyte regulation adds a fourth biological dimension — supporting the cellular renewal and gene expression environment within the follicular epithelium that the vascular and hormonal actives do not directly address.

Bedtime application maximizes all four actives: Tretinoin's photolability and photosensitizing activity require nighttime application. Minoxidil benefits from prolonged contact time. The scalp's nocturnal permeability enhancement supports absorption of all four actives. Once-nightly bedtime application is the optimal delivery schedule for every component of this formula simultaneously.

With consistent nightly application as directed by your prescribing provider:

Reduced intrafollicular DHT through dual-isoform 5-alpha reductase inhibition — finasteride (type II) and progesterone (type I) simultaneously

Additional receptor-level androgenic protection through progesterone's competitive androgen receptor binding

Prolonged anagen growth phase and improved perifollicular microcirculation through minoxidil's vasodilatory and VEGF-mediated mechanisms

Enhanced minoxidil, finasteride, and progesterone scalp penetration and follicular bioavailability through tretinoin's stratum corneum permeabilization

Direct follicular keratinocyte regulation through tretinoin's RAR-mediated cellular activity

Preservation of existing hair density in follicles with remaining growth capacity

Support for regrowth in thinning areas as follicles released from DHT-driven miniaturization respond to growth stimulation

Improved hair shaft caliber and structural quality with sustained treatment

A comprehensive, precisely concentrated four-mechanism topical approach in a single nightly application

Results vary by individual, age, extent of hair loss, and follicular reserve at treatment initiation. Meaningful improvement in density and shedding rate typically develops over three to six months of consistent nightly use. Maximum benefit is generally seen at twelve months and beyond. The protective effect of finasteride reverses with discontinuation — ongoing nightly application is the clinical expectation.

Apply topically to affected scalp areas at bedtime.

Application Instructions:

Ensure the scalp is clean and completely dry before application. Allow at least 20–30 minutes after showering — tretinoin penetrates more aggressively into damp or recently wetted skin, increasing irritation risk.

Part hair to expose affected scalp regions — typically the vertex, crown, and any areas of visible thinning.

Apply the directed amount of solution — as specified by your provider — directly to affected areas using the applicator or dropper, distributing evenly across the treatment zone.

Thoroughly massage into the scalp using fingertips with gentle circular motions, ensuring even coverage and promoting follicular absorption.

Allow to dry fully. Do not rinse. The solution must remain on the scalp overnight.

Wash hands thoroughly immediately after application. This formula contains finasteride — which can cause fetal harm through skin contact — and testosterone-related hormonal actives. Minimize hand contact and wash hands promptly and completely after each application.

Do not apply other scalp products until the solution has fully absorbed.

Bedtime application is mandatory — tretinoin is photolabile and degrades on UV exposure. Morning application negates tretinoin's activity and dramatically increases photosensitivity risk. Apply only at night.

Sun protection: Although this is a bedtime-only formula, tretinoin increases photosensitivity — daily broad-spectrum SPF on the scalp (or hair coverage) is recommended throughout treatment, particularly for patients with thinning areas of exposed scalp skin.

If a dose is missed: Apply when remembered on the same day, or resume regular schedule at the next planned application. Do not double-apply.

This is a prescription-only compounded medication containing finasteride, a teratogenic 5-alpha reductase inhibitor, and tretinoin, a teratogenic retinoid. Women of childbearing potential must not handle this product.

Contraindications:

Pregnancy — absolute contraindication: This formula contains two independently teratogenic actives. Tretinoin is associated with fetal abnormalities. Finasteride is associated with abnormalities of the external genitalia in male fetuses — and can be absorbed through skin contact with the solution. Women who are pregnant or may become pregnant must not use or handle this product in any form. Reliable contraception is required for women of reproductive age using this formula. Discontinue immediately and contact your provider if pregnancy occurs.

Women of childbearing potential — handling prohibition: Even women not using this formula themselves must not handle it if they are pregnant or may become pregnant. Secondary skin contact with finasteride-containing solutions is a documented exposure route. Store where pregnant women and women of childbearing potential cannot access it.

Pediatric patients: Not indicated for patients under 18 years of age.

Known hypersensitivity: Patients with documented allergy to minoxidil, tretinoin, finasteride, progesterone, or any vehicle component should not use this product.

Significant cardiovascular disease: Minoxidil retains systemic vasodilatory activity through topical absorption. Patients with significant cardiovascular conditions require individualized provider evaluation before initiating.

Potential Side Effects:

Tretinoin-related:

Scalp dryness, flaking, or mild irritation during the initial adjustment period — typically the first two to four weeks; usually transient; reduce application frequency temporarily if severe

Increased scalp photosensitivity — managed by daily SPF and avoiding prolonged direct sun exposure on thinning scalp areas

Mild scalp erythema during adjustment period

Finasteride-related (topical — lower systemic exposure than oral):

Sexual side effects — decreased libido, erectile dysfunction, reduced ejaculate volume — reported less frequently with topical than oral finasteride due to lower systemic absorption; remain possible; discuss promptly with your provider if experienced

Local scalp sensitivity or contact reaction — uncommon; discontinue and consult provider if persistent

Minoxidil-related:

Scalp irritation, itching, or flaking — particularly early in treatment; often related to vehicle components; typically resolves with continued use

Transient increased shedding during weeks four to eight — follicles transitioning from resting to active phase; expected and temporary; do not discontinue without provider consultation

Rare unintended facial hair growth adjacent to application areas — minimize by careful application within the scalp margin

Rare systemic cardiovascular effects from absorption — palpitations, fluid retention; report promptly

Progesterone-related:

Mild local scalp sensitivity in patients with progesterone sensitivity

Rare systemic progestogenic effects with significant absorption — drowsiness, mood changes; report if experienced

General:

Contact dermatitis in patients with sensitivity to any formula component or vehicle ingredient

Oral finasteride or dutasteride: Combined systemic and topical 5-alpha reductase inhibition requires clinical coordination. Inform your provider of all concurrent finasteride or dutasteride use.

Other topical retinoids: Concurrent use of additional retinoid-class products on the same scalp area significantly increases irritation risk. Do not combine without provider direction.

Antihypertensive medications: Topical minoxidil has vasodilatory activity — additive blood pressure effects are unlikely at hair loss application volumes in otherwise healthy patients but warrant disclosure to all providers.

Systemic hormonal therapies: Patients on systemic estrogen, progesterone, testosterone, or other hormonal therapy should ensure all prescribing providers are aware of the progesterone and finasteride components of this formula.

Photosensitizing medications: Tretinoin's photosensitizing activity is additive with other photosensitizing agents. Inform all providers of tretinoin-containing scalp therapy before prescribing photosensitizing antibiotics, diuretics, or antifungals.

Other topical scalp treatments: Apply in sequence with adequate absorption time between products. Discuss all concurrent scalp treatments with your provider.

Store at room temperature, 68°F – 77°F (20°C – 25°C), away from direct heat, humidity, and light

Tretinoin is light-sensitive — keep in original packaging away from direct sunlight

Keep container tightly closed between uses

Do not freeze

Keep strictly out of reach of women of childbearing potential and children — finasteride must not be handled by pregnant women or women who may become pregnant

Do not use beyond the labeled expiration date